• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services

Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy
Artificial intelligence (AI) and machine learning have great potential to improve people’s lives. From supporting data analysis in research to providing more accurate and quicker diagnostic tools. But their interior workings are questioned by many and understood by few. New models are needed to solve current shortcomings and causal AI might be our way out. By offering a peek inside the black box, it creates opportunities to implement AI in high-risk settings such as healthcare. But how far along are we and where is this journey taking us?
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
Microalgae have been proposed as a potential source for numerous products, ranging from proteins used in nutrition to mycosporine-like amino acids (MAA) that could be used in sunscreens to absorb ultraviolet (UV) light. However, one of the major constraints to using microalgae-based products is their low production of high-value products like MAA. GeneBEcon, a Horizon Europe-funded project, investigates the potential to increase the production of valuable compounds in microalgae through gene editing in order to enable a more sustainable bioeconomy in Europe.
The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) is a standardized framework designed by the Observational Health Data Sciences and Informatics (OHDSI) community. This open-science community aims to improve the quality of healthcare by providing guidelines for a more harmonized approach to data science.
In a world where our health is paramount, fatty liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is climbing the ranks of health concerns we can't afford to ignore. Imagine your liver, which controls over 500 vital functions, including the body's detox powerhouse, getting clogged with fat. Alarmingly, about 30% of people globally are wrestling against this silent epidemic. It's a complex disease with various risk factors, especially related to gender and sex hormonal differences, making a one-size-fits-all treatment difficult.
The number of offshore wind farms in the North Sea is exponentially increasing. Their construction responds to the urgent need to transition to green energy production and carbon neutrality. The installation of these man-made structures has a notable impact on the marine ecosystem. Some positive impacts include providing a new home for various animals, and offering shelter, food, and breeding grounds. However, there have been observations of black sediment patches in the sampled sediments near the turbine foundations, suggesting a high input of organic matter into the sediment, altering natural biogeochemical processes.
After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy
Artificial intelligence (AI) and machine learning have great potential to improve people’s lives. From supporting data analysis in research to providing more accurate and quicker diagnostic tools. But their interior workings are questioned by many and understood by few. New models are needed to solve current shortcomings and causal AI might be our way out. By offering a peek inside the black box, it creates opportunities to implement AI in high-risk settings such as healthcare. But how far along are we and where is this journey taking us?
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
Microalgae have been proposed as a potential source for numerous products, ranging from proteins used in nutrition to mycosporine-like amino acids (MAA) that could be used in sunscreens to absorb ultraviolet (UV) light. However, one of the major constraints to using microalgae-based products is their low production of high-value products like MAA. GeneBEcon, a Horizon Europe-funded project, investigates the potential to increase the production of valuable compounds in microalgae through gene editing in order to enable a more sustainable bioeconomy in Europe.
The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) is a standardized framework designed by the Observational Health Data Sciences and Informatics (OHDSI) community. This open-science community aims to improve the quality of healthcare by providing guidelines for a more harmonized approach to data science.
In a world where our health is paramount, fatty liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is climbing the ranks of health concerns we can't afford to ignore. Imagine your liver, which controls over 500 vital functions, including the body's detox powerhouse, getting clogged with fat. Alarmingly, about 30% of people globally are wrestling against this silent epidemic. It's a complex disease with various risk factors, especially related to gender and sex hormonal differences, making a one-size-fits-all treatment difficult.
The number of offshore wind farms in the North Sea is exponentially increasing. Their construction responds to the urgent need to transition to green energy production and carbon neutrality. The installation of these man-made structures has a notable impact on the marine ecosystem. Some positive impacts include providing a new home for various animals, and offering shelter, food, and breeding grounds. However, there have been observations of black sediment patches in the sampled sediments near the turbine foundations, suggesting a high input of organic matter into the sediment, altering natural biogeochemical processes.
After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?